AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01824394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nMARQ Navigation Catheters
Study NCT01824394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaviStar ThermoCool Catheters
Study NCT03276884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: amino acid-based infant formula powder
Study NCT03276884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: amino acid-based infant formula powder
Study NCT02584335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine solution (A)
Description: Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception.
Study NCT02241785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm
Study NCT02584335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution (B)
Description: Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception.
Study NCT03898141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PL)
Description: Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain.
Study NCT03898141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dog only (DO)
Description: In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).
Study NCT03898141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted placebo (AAPL)
Description: Participants receive the placebo intervention in the presence of a dog.
Study NCT02842918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manual Therapy
Study NCT02842918 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Spinal Manual Therapy
Study NCT02842918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Range of Motion
Study NCT02842918 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Spinal Range of Motion
Study NCT00939250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes and depression intervention
Description: Disease self management for diabetes and depression
Study NCT00939250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes intervention
Description: Disease self management for diabetes
Study NCT00719251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High voltage pulsed current
Description: The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
Study NCT00719251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
Study NCT00719251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard nursing care
Description: It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
Study NCT01915914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
Study NCT01915914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
Study NCT04700202 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
Study NCT02867189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: atlas of micro-instrument
Description: Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
Study NCT02792556 — intervention group
Intervention type: DEVICE
Intervention: Urine pregnancy test
Description: Urine pregnancy test Check Top after transvaginal ultrasound
Study NCT03569748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-CIG
Description: ELECTRONIC CIGARETTE FOR 12 WEEKS
Study NCT02299479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum CGM
Description: Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
Study NCT02299479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
Study NCT01132404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
Study NCT01132404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months
Study NCT00543348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CUTTING BALLOON ANGIOPLASTY
Description: CUTTING BALLOON
Study NCT00543348 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CUTTING BALLOON ANGIOPLASTY
Description: CUTTING BALLOON
Study NCT00543348 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Balloon angioplasty
Description: HIGH PRESSURE BALLOON
Study NCT00079118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00079118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT02189746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Kangaroo Mother Care to 1 hour after birth
Description: Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
Study NCT02189746 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Kangaroo Mother Care to 1 hour after birth
Description: Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
Study NCT02189746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Kangaroo Mother Care to discharge
Description: Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
Study NCT02189746 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Kangaroo Mother Care to discharge
Description: Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
Study NCT02702505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoMTA
Description: A new formulation of MTA was developed in which bismuth oxide was omitted
Study NCT02702505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ProRoot MTA
Description: Control group
Study NCT00696696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Study NCT00696696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Study NCT00613405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress + cue exposure
Description: Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
Study NCT00613405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No stress + cue exposure
Description: Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
Study NCT01513603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAG-M
Description: IV times 5 days
Study NCT01513603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAG-M
Description: Chemotherapy
Study NCT04315792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen
Description: Administration of Endoxifen for 3 weeks
Study NCT04315792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Administration of Placebo for 3 weeks
Study NCT02388490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
Study NCT01926080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DVD Intervention Arm
Description: Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
Study NCT04231331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertugliflozin
Description: Ertugliflozin 5mg qd for 12 months
Study NCT04231331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo qd for 12 months
Study NCT03087071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02147093 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Test (multi-focal)
Description: contact lens was to be worn a daily wear.
Study NCT02147093 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control (Sphere)
Description: contact lens was to be worn a daily wear with spectacles
Study NCT04436016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.
Study NCT04436016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol will be encapsulated for adequate blinding.
Study NCT04436016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol will be encapsulated for adequate blinding.
Study NCT03428633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Paravertebral block using ropivacaine preoperatively and postoperatively
Study NCT03428633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine intraoperatively and postoperatively
Study NCT03759249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep medical treatment
Description: The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion.
Study NCT00960206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
Description: Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
Study NCT00960206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
Description: Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
Study NCT00960206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
Description: OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
Study NCT04677400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: More than Body Appearance (MBA) Intervention
Description: The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them.
Study NCT04677400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: More than Body Appearance (MBA) Intervention
Description: The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them.
Study NCT00696696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Study NCT03905512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: Administered as specified in the treatment arm
Study NCT02512237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: ARX788, an antibody drug conjugate
Study NCT01711970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT04687878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: 20 IU twice a day, intranasally, every day for 12 weeks
Study NCT03905512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRYSTEXXA®
Description: Administered as specified in the treatment arm